KARLAVAGEN 100, 115 26, STOCKHOLM, V7
Reports Quarter Ended June 30, 2026 Financial Results
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Shareholder votes
Reports 2025 Financial Results
Reports Quarter Ended September 30, 2025 Financial Results
Announces Anticipated Financial Proceeds from Patent Lawsuit Settlement
Reports Quarter Ended June 30, 2025 Financial Results
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload
Definitive Revised Proxy Statement